Genomines has secured $45 million in Series A funding to scale its innovative plant-based nickel production, aiming to transform the metal extraction industry towards sustainability.
Target Company Overview
Genomines, a pioneer in the field of Phytomining, has successfully raised $45 million in a Series A funding round to enhance its plant-based nickel production capabilities. The company’s innovative platform utilizes hyperaccumulator plants to extract nickel for batteries, offering a method that is faster, more economical, and environmentally friendly compared to traditional mining techniques. Renowned industry partners, including Hyundai Motor Group and Jaguar Land Rover, have already engaged with Genomines, demonstrating the industry's confidence in its technology.
The latest funding follows a previous seed round of $5 million and an additional $12 million in non-dilutive capital, consolidating Genomines’ total funding to $62 million. The capital will primarily be used to support pilot projects in South Africa aimed at scaling their extraction processes and securing significant off-take agreements with leading industrial stakeholders, further validating their market potential.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in South Africa
South Africa has long been recognized as a major player in the mining sector, particularly for its rich deposits of minerals such as gold, platinum, and nickel. However, conventional mining practices are often criticized for
Similar Deals
Exxaro Resources Limited → Ntsimbintle Holdings Proprietary Limited and OMH (Mauritius) Corp
2025
EverSeed Energy Proprietary Limited → Exxaro FerroAlloys Proprietary Limited
2025
Engine Ventures, Forbion BioEconomy, DeepTech & Climate Fonds, Wind, Hyundai Motor Group, Teampact Ventures, Prospect Innovation, Raise Phiture, AlphaTech Investment Group
invested in
Genomines
in 2025
in a Series A deal
Disclosed details
Transaction Size: $45M